Target and Technology

SGN-2FF is an oral, small molecule immuno-oncology agent that has been shown in preclinical models to inhibit fucosylation of proteins. Targeting fucosylation is a novel strategy in cancer therapy. Fucosylation plays an important role in both cancer and immune cells, and inhibition of fucosylation may stimulate the immune system to slow the growth and spread of cancer cells.

Clinical Development Status

  • Phase 1 trial evaluating the safety and antitumor activity of SGN-2FF in patients with relapsed/refractory solid tumors, including non-small cell lung cancer

SGN-2FF is an investigational agent, and its safety and efficacy have not yet been established.